2
Here, we present cDriver, a novel Bayesian inference approach to identify and rank 1 3 mutational driver genes using multiple measures of positive selection. We benchmark our 1 4
results against standard tools on public tumor datasets. Finally, we apply cDriver to 6,870
1 5
cancer exomes to uncover associations between driver genes and tumor types, identifying 1 6
novel connections highly enriched for chromatin modifying proteins, expanding the current set 1 7
of prognostic markers for cancer treatment. To identify driver genes, we have developed cDriver ( Supplementary Fig. 1 , online 2 2 missed several tumor suppressor genes, since loss of function mutations in these genes do 1 not necessarily cluster (e.g. PBRM1, Supplementary Fig. 5b ). MutsigCV missed KEAP1 and 2 MTOR in this dataset, but it was able to find these genes with larger sample size 13 .
3
We next investigated whether cDriver identifies a particular function commonly missed by 4 oncodriveFM by looking at significant genes in only one of the methods using Gene Ontology 5 analysis (Supplementary Fig. 12a ). Interestingly, we found that tyrosine kinase related 6 genes were enriched in the group of genes predicted only by cDriver ( Supplementary Fig.   7 12c). Tyrosine kinase related genes have a well-described role in tumor initiation, mostly 8 associated to oncogenes 61 , reflecting the importance of CCF as an independent 9 discriminatory signature in addition to functional impact (oncodriveFM). Conversely, 1 0
processes enriched in the group of genes predicted only by oncodriveFM were related to 1 1 binding activity (Supplementary Fig. 12d ).
In summary, cDriver performed favorably in individual tumor types and in Pancan12 1 3
independently of applied GS, allowing us to explore an extended landscape of driver genes 1 4
across multiple tumor types.
1 5 1 6
Tumor type -driver gene landscape across 21 cancers 1 7
To obtain a comprehensive list of driver genes in an extended TCGA dataset, we ran cDriver 1 8
on each and on a pooled set of 21 tumor types comprised of 6,870 samples (Pancan21, 1 9 Supplementary Table 4 ). While on average the median number of significant driver genes 2 0 detected per tumor type was 31 ( Supplementary Table 6 ), we observed that several genes 2 1 in the 'long tail' were a) close to significance, b) mutated in a large fraction of patients, and c) connected tumor type ( Supplementary Table 7 ). Furthermore, the network of these genes 1 had significantly more interactions than expected in the STRING database (Adj. P 2 value=2.22e-15, Supplementary Fig. 8) . Surprisingly, 18 of these interacting genes were 3 annotated as chromatin modifiers in the gene ontology database (Adj. P value=1.3e-10, 4 STRING) and were significantly enriched also when considering only cancer genes (18 out of 5 63 versus 78 out of 504 CGC, Fisher's exact P Value=0.0125), revealing an underappreciated 6 role of chromatin modification and chromatin organization in several tumor types. Importantly, 7 we found that in 18 out of 21 tumor types, 20% to 80% of patients were affected by a 8 mutation in one of these chromatin-modifying proteins (Supplementary Fig. 9) , with an 9 average of 40.2% across all tumor types.
1 0
Finally, we individually investigated the TTDG connections of two known therapeutic targets, 1 1 CHD4 ( Fig. 5a ) and SMARCA4 (Fig. 5b) . We found that chromodomain helicase 4, CHD4, 1 2 acts as a driver for seven tumor types, while initially it was only associated to endometrial 41 1 3
and ovarian carcinoma ( Fig. 5c ). CHD4 is a tumor suppressor and core member of the and neck and liver carcinomas ( Fig. 5d) . It is the core subunit of a SWI/SNF complex and has 2 2 several binding motifs to other tumor suppressors proteins 47, 48 . Most of the mutations fall in 2 3 the active domains SNF2 (Fig. 5b) involved in the unwinding of the DNA. Additionally, we 2 4 observed that liver carcinoma patients carrying a mutation in SMARCA4 have a poor 2 5 prognosis ( Fig. 5f) . In summary, all novel TTDG connections could be exploited as potentially 2 6 therapeutic targets ultimately increasing the number of options for cancer prognosis. purity and tumor ploidy, as well as adequate coverage of mutated positions. We expect that 2 0 ultra-deep and single cell sequencing will further improve the power to detect mutations in 2 1 small fractions of the tumor, making CCF an indispensable feature for accurate driver gene 2 2 prediction.
3
Different types of driver genes are functionally constrained by different evolutionary pressures.
4
Therefore, combining complementary signatures for mutational driver identification 28 , we 2 5
show that functional impact and CCF equally improve performance, and their combination 2 6 outperforms the use of each independently. Interestingly, genes missed by oncodriveFM 2 7 (functional impact bias) but identified by cDriver (using CCF and functional impact) are 2 8 enriched in a well-known group of genes involved in tumor initiation, the tyrosine kinases.
9
These results indicate that selection signatures at the molecular, cell, and population level are 3 0 complementary, likely due to different underlying biological principles. In addition, we 3 1 demonstrate that cDriver improves performance when combined with canonical methods, 3 2 ultimately detecting infrequently mutated driver genes missed by other approaches.
3
The total number of cancer genes driving tumorigenesis is still incomplete. Multiple gold tumorigenesis not related to positive selection of nonsilent point mutations. Indeed, all 1 methods tested here neglect other types of complex variation that may be driving cancer 2 malignancy. These events are also under selection such as, positive selection of copy 3 number alterations, fusion genes, regulatory, and synonymous mutations, as well as negative 4 selection of cancer essential genes.
5
Our study also highlights the importance of prior information on driver gene prediction. A gene 6 that is highly mutated (known driver) in one tumor type is probably a driver in other tumor 7 types, even if it is infrequently mutated. We show that 63 genes highly ranked in one tumor genes are interacting or co-localized, suggesting that a single hit is needed to drive 1 4
tumorigenesis. Indeed, we found that mutations in the 18 chromatin-modifying proteins affect 1 5 a large fraction of cancer patients ( Supplementary Table 7 ). The genes CHD4 and 1 6
SMARCA4 demonstrate how the landscape of tumor type -driver gene connections can be 1 7
exploited to identify novel therapeutic targets, especially for patients without a canonical 1 8 driver mutation.
9
In conclusion, we show that an extensive landscape of therapeutic targets awaits exploration.
0
We demonstrate that integrating cellular prevalence of somatic mutations as part of multiple 2 1 signatures of tumor evolution allows for improved discovery of driver genes. As a result, it 2 2 facilitates identification of novel tumor type -driver gene connections, which are key for 2 3 improved cancer diagnosis, monitoring, and targeted treatment selection.
2 4 2 5
Methods
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Methods and any associated references are available in the online version of the paper. 
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The authors declare no competing financial interests. applying a sigmoid transformation to CADD scores 53 with mean and scale factor of 2.
Individual MAF files for each cancer were produced in order to perform downstream analysis.
8
Expression values for this dataset were also obtained from synapse (syn1729383).
9
Pancan21 somatic mutation data. The MAF files for 6,485 exome samples from 20 2 0 tumor types were downloaded from DCC-Firehose and combined with 385 CLL cases to 2 1 obtain a large dataset of 21 tumor types ( Supplementary Table 4 ). Allele counts were 2 2 transformed to VAF and CADD scores were added for each mutation. We removed 2 3 duplicated samples and updated the gene symbols using the Hugo Gene Symbol database.
4
Colon and rectal tumors were merged into one tumor type giving us a final set of 20 tumor 2 5
types. All curated MAF files used in this study were uploaded to synapse (syn5593040).
6
CLL somatic mutation data. 385 CLL tumor-normal pairs sequenced by WES were 2 7 analyzed using an in-house pipeline. Reads were aligned to hg19 using BWA-mem 54 and 2 8
BAM files were post-processed (indel realignment, base quality recalibration) using GATK Fig. 1 ). cDriver uses a 
9
One of the conceptual advances of our method is the inclusion of cancer cell fraction 3 0 3 5
To account for the variability of the background mutation rate (bmr) between genes, 3 6 cDriver uses silent mutations to locally estimate the expected number of nonsilent mutations.
restricting the usefulness of Ka/Ks. Therefore, cDriver calculates an average bmr using the known driver genes (e.g. any gold standard used in this study) to estimate prior and likelihood 6 values. The "cancer-hazard model" estimates the posterior probability of developing cancer if 7 the focal gene is mutated, given evidence from the data, i.e. somatic mutations of the gene in 8 a cohort of cancer patients. The "driver inference model" estimates the posterior probability 9 that a gene is a true cancer driver given evidence from the data.
0
As a final step, cDriver can provide an optimum rank-cut off value by estimating FDR 1 1
at each rank based on a null model. cDriver default estimates the optimum rank for each 1 2
Bayesian model and suggest the best rank cut-off as the average value between both ranks.
3
In summary, cDriver combines recurrence, CCF, and functional impact as a 1 4
foreground measure, and an averaged background mutation probability as a measure to 1 5
calculate posterior probabilities for each gene. In the next sections each step is described in 1 6
detail.
1 7 1 8
Step 1) Estimation of cancer cell fraction per gene.
1 9 CCF calculation. We developed a function for estimation of Cancer Cell Fraction (CCF) per 2 0 gene as part of the cDriver package (for details see Supplementary note), although any 2 1 method can be used to estimate the CCF subsequently used for driver prediction (e.g.
2
PyClone). Intuitively, we assumed that the variant allele should be observed in approximately 2 3
half of the reads if it is a clonal heterozygous variant in a diploid locus. In this case, CCF is 2 4 calculated as the variant allele frequency (VAF) multiplied by two and corrected for the purity 2 5 of the cancer sample. All other cases are described in the supplementary note.
2 6 2 7
Step 2) Background mutation rate models. 
Next, we adapted the formula to take into account cancer cell fraction of mutations by 
7
We set the number of trials, r, to the average number of mutations per patient in the cohort. In 
is a probability for a gene X to have no nonsilent mutations, and derived as
6
Background mutation probability based on other mutation rate estimates. To we determined the expected number of nonsilent mutations following a rearrangement of the 1 2 classical formula into:
Similarly to the previous model, we calculated the probability that a gene has at least 1 4
one nonsilent mutation using the binomial distribution formula, but without CCF:
Given the continuous progress on technologies, it is likely that more specific somatic mutation 1 7
rates will be calculated in the future, so in addition cDriver could integrate any measure of 1 8
background mutation rate. Here, we used as final background mutation probability (bmp) the 1 9
average bmp obtained by the two methods described above (CCF-adjusted ‫ܭ‬ ‫ܭ‬ ௦ ⁄ and ncmr).
2 0 2 1
Step 3) Bayesian inference models 2 2
Cancer-hazard inference model. In the first model, we adapted Bayes formula to calculate a 2 3 posterior probability of developing cancer given that a focal gene is mutated as
nonsilent mutation in a gene of interest is estimated from the cohort. To this end, we used 1 the sum of CCF times the adjusted-CADD damage probability per gene across all patients:
where is the index of the patient and n the total size of the cohort. If a patient did not have 3 any nonsilent mutation, then CCF was equal to zero. If two nonsilent mutations were found in 4 a patient in the same gene of interest, we used the mutation with the highest CCF.
5
We defined the marginal probability of having a nonsilent mutation as the sum of the 6 numerator of (1), plus the conditional probability of having a nonsilent mutation in a healthy
times the probability of a healthy individual
as the somatic background mutation probability (bmp). To our 9 knowledge there is no large enough cohort of healthy people examined for tissue specific 1 0 somatic mutations, therefore direct estimation from data is not possible. However, we 1 1 estimated an upper bound of the bmp as described in the previous section. gene is a cancer driver given the mutation data in the studied cohort using the formula:
and ݊ is total size of the cohort.
6
To estimate a prior probability of a gene being a driver we need to consider that most 1 7
tumor types can be caused by mutations in a different set of genes. Depending on which 1 8
tumor type or group of cancers ('pan-cancer') we were analyzing, the number of known driver 1 9
genes differs and hence the prior probabilities change (e.g. ovarian cancers are in most 2 0 cases caused by mutation in TP53, while the number of published genes involved in CLL 2 1 ranges from 20 to 40, depending on the study). We estimated the prior probability that a 2 2 random gene is a driver as equal to the ratio between the number of known driver genes of 2 3 the cancer type and the total number of protein coding genes:
2 5
The number of driver genes can be approximated as the number of published driver 2 6
genes for a particular cancer type. If the cancer has not been studied yet, or if we deal with 2 7
pan-cancer sets of multiple cancer types, the prior can be approximated using any gold 2 8 standard list of cancer driver genes.
9
Because of inter-tumor heterogeneity genes that are known to be cancer drivers in a 3 0
given tumor type will not necessarily be mutated in all patients. The probability that a gene is 3 1 mutated given that it is a known driver can be estimated as: ݉  ‫ݑ‬  ‫ݐ‬  |  ݀  ‫ݎ‬  ݅  ‫ݒ‬  ݁  ‫ݎ‬  ሻ  ൌ  #  ݉  ‫ݑ‬  ‫ݐ‬  ܽ  ‫ݐ‬  ݅  ‫‬  ݊  ‫ݏ‬  ݅  ݊  ݀  ‫ݎ‬  ݅  ‫ݒ‬  ݁  ‫ݎ‬  ‫ݏ‬  #  ‫‬  ܽ  ‫ݐ‬  ݅  ݁  ݊  ‫ݐ‬  ‫ݏ‬  ‫כ‬  #  ݀  ‫ݎ‬  ݅  ‫ݒ‬  ݁  ‫ݎ‬  ‫ݏ‬   (11) where we assume that all drivers have the same chance to be mutated. As this assumption is 1 weak the cDriver package allows the user to define better estimates for this likelihood.
2
The probability that a gene is mutated given that it is not a driver
is estimated from the background mutation rate as described 4 previously.
5
The other terms in the equation, 
9
Step 4) Optimum rank cut off selection 1 0
Significant rank selection based on weighted sampling of a null model. To generate an 1 1 optimum rank cut off for our two bayesian models, we calculated a null model based on 1 2 random assignment of new gene labels based on the background mutation probability (bmp) 1 3
vector. The BMP vector is generated from the observed silent mutation data as described 1 4
previously. Then, we run our Bayesian model as we would with the cancer cohort to obtain 1 5 posterior probabilities per gene under a null model. We repeat this 100 times to be sure that 1 6
probabilities are stable between each run and we are not catching unlucky random 
0
The gold standard genes for breast cancer consisted of the union of dataset (7), and 1 1 breast cancer genes found in (2) and (4) plus the top 20 genes identified in COSMIC. For CLL 1 2
we merged dataset (6) and CLL genes found in (2) and (4) plus the top 20 genes identified in 1 3
COSMIC. Subsequently, we manually curated this list by checking the number of PubMed against the tumor specific gold standards assembled as described above. In addition, we 1 9
compared the performance of the methods on Pancan12 with and without filtration of non-2 0 expressed genes.
1
Furthermore, we benchmarked our method cDriver under several scenarios and cDriver. For this, we calculated a combined rank and calculate the Fscore. We used "Borda 2 9
count" ranking method with truncated ranks (up to two times the gold standard size) but using 3 0 ranks of only the three best methods.
For visualization purposes we show only genes that were ranked up to twice the 3 2 number of gold standard genes given no further improvement was achieved by any tool 3 3 beyond these thresholds.
4 5
Defining the landscape of tumor type-driver gene connections in Pancan21. We ran 3 6 cDriver on each of the 21 tumor types separately (syn5593040, Supplementary Table 4 ) and
genes, we noted their presence among the top 100 ranked genes of each tumor type to 1 define a "tumor type -driver gene" (TTDG) connection. We defined genes found in the top 10 2 of only one tumor type and not in the top 100 of any other tumor type as highly tumor specific. 
1
We obtained the CCF distribution for nonsilent driver, nonsilent passenger, silent driver, and 1 2 nonsilent passenger gene mutations and compared the significance of the differences 1 3 between each pair of them. CCF of nonsilent driver mutations is significantly higher compared 1 4
to all other groups. Importantly, CCF of nonsilent driver is significantly higher compared to 1 5 silent mutations in driver genes and the latter were not significantly different from silent or 3 F-score for cDriver (solid blue line) and four other driver identification algorithms using BRCA 4 (a) and CLL (b) datasets. Results of each method were transformed to ranks by ordering P 5 values or posterior probabilities. The P value cutoff for significance is shown as a circle in 6 each of the curves. For visualization, F-score is shown to rank 66 for BRCA and 44 for CLL 7 (twice the number of genes in the gold standards), since all methods reach the F-score peak 8 before these ranks (c, d). We compared the results for all methods irrespective of the P value 9 using only the ranking for BRCA (c) and CLL (d). Gold standard genes were ordered by 1 0 mutation frequency and samples were ordered by cancer cell fraction (CCF). The CCF of 1 1 each mutation in each gene-patient pair is indicated by the red color gradient. On the right, 
